| 1 | 08:00-08:25 | 专题报告 |
儿童急性白血病微小残留白血病的进展与挑战 |
|
||||
| 2 | 08:25-08:50 | 专题报告 |
CART在儿童疾病中的应用-上海儿童医学中心经验 |
|
||||
| 3 | 08:50-09:15 | 专题报告 |
儿童血栓性血小板减少性紫癜诊治进展 |
|
||||
| 4 | 09:15-09:25 | 讨论 |
集体答疑、讨论 |
|||||
| 1 | 09:25-09:30 | 大会发言 |
Single-Cell Multi-Omics Reveals GBP1/5⁺ Mononuclear Phagocytes as Key Drivers in EBV-HLH Immune Crosstalk and Metabolic Reprogramming |
|
||||
| 2 | 09:30-09:35 | 大会发言 |
儿童MLL重排阳性急性淋巴细胞白血病的多中心研究 |
|
||||
| 3 | 09:35-09:40 | 大会发言 |
急性淋巴细胞白血病患儿化疗期间首次院内感染的临床特征及相关危险因素分析 |
|
||||
| 4 | 09:40-09:45 | 大会发言 |
儿童急性淋巴细胞白血病复发治疗变迁及预后因素分析 |
|
||||
| 5 | 09:45-09:50 | 大会发言 |
1027例儿童异基因造血干细胞移植后EB病毒感染的临床分析 |
|
||||
| 6 | 09:50-09:55 | 大会发言 |
儿童单倍体造血干细胞移植中供者KIR与患者HLA-C的协同影响预后:153 例回顾性队列研究 |
|
||||
| 7 | 09:55-10:00 | 大会发言 |
单中心20例急性早幼粒细胞白血病患儿远期随访分析 |
|
||||
| 8 | 10:00-10:05 | 大会发言 |
原发血液性疾病继发肺出血相关临床特征及预后分析 |
|
||||
| 1 | 10:05-10:30 | 专题报告 |
细胞死亡调控与儿童白血病的精准诊疗 |
|
||||
| 2 | 10:30-10:55 | 专题报告 |
儿科遗传性血液肿瘤综合征的诊治策略 |
|
||||
| 3 | 10:55-11:20 | 专题报告 |
儿童造血干细胞移植肺损害研究进展 |
|
||||
| 4 | 11:20-11:30 |
集体答疑、讨论 |
||||||
| 1 | 11:30-11:35 | 大会发言 |
初诊儿童再生障碍性贫血外周血免疫细胞分析全景图 |
|
||||
| 2 | 11:35-11:40 | 大会发言 |
A CLA versus DAC bridging chemotherapy regimen prior to PTCy-HSCT in pediatric acute myeloid leukemia |
|
||||
| 3 | 11:40-11:45 | 大会发言 |
Identification and diagnostic capacity for Pediatric Inherited Platelet Disorders in China: A National Survey |
|
||||
| 4 | 11:45-11:50 | 大会发言 |
PICASO方案清除DSA序贯haplo-HSCT治疗DSA强阳性地贫患儿的疗效分析 |
|
||||
| 5 | 11:50-11:55 | 大会发言 |
异基因造血干细胞移植治疗APDS患儿10例预后及免疫重建分析 |
|
||||
| 6 | 11:55-12:00 | 大会发言 |
Differentiating primary bone marrow failure syndromes in children: a retrospective analysis of early clinical and laboratory features |
|
||||
| 1 | 13:30-13:55 | 专题报告 |
遗传背景与血液增殖性疾病 |
|
||||
| 2 | 13:55-14:20 | 专题报告 |
地中海贫血规范化治疗及管理 |
|
||||
| 3 | 14:20-14:45 | 专题报告 |
免疫治疗在儿童B-ALL的临床应用 |
|
||||
| 4 | 14:45-14:55 | 讨论 |
集体答疑、讨论 |
|||||
| 1 | 14:55-15:00 | 大会发言 |
单细胞转录组孟德尔随机化与多组学整合分析揭示可成药基因PLTP是急性髓系白血病免疫调控的潜在药物治疗靶点 |
|
||||
| 2 | 15:00-15:05 | 大会发言 |
难治复发儿童ALL患者CAR-T序贯allo-HSCT临床疗效分析 |
|
||||
| 3 | 15:05-15:10 | 大会发言 |
联合NEU计数和cfCMV DNA检查可在移植后儿童患者中有效鉴别CMV肠炎和肠道GVHD |
|
||||
| 4 | 15:10-15:15 | 大会发言 |
Effect of mucosal-associated invariant T cells on gut acute graft-versus-host disease after hematopoietic stem cell transplantation |
|
||||
| 5 | 15:15-15:20 | 大会发言 |
奥加伊妥珠单抗联合贝林妥欧单抗联合治疗高危组B细胞急性淋巴细胞白血病临床观察 |
|
||||
| 6 | 15:20-15:25 | 大会发言 |
单倍体造血干细胞移植治疗小儿急性白血病首次移植后复发的结果及预测因素 |
|
||||
| 7 | 15:25-15:30 | 大会发言 |
儿童B-ALL化疗全程外周血淋巴细胞亚群及功能的动态变化分析 |
|
||||
| 8 | 15:30-15:35 | 大会发言 |
基于NGS技术的Ig/TCR基因克隆性重排在儿童ALL微小残留病监测中的应用研究 |
|
||||
| 1 | 15:35-16:00 | 专题报告 |
儿童/青少年复发难治性T-ALL&LBL治疗进展 |
|
||||
| 2 | 16:00-16:25 | 专题报告 |
遗传性血小板减少症诊治进展 |
|
||||
| 3 | 16:25-16:30 | 讨论 |
集体答疑、讨论 |
|||||
| 1 | 16:30-16:35 | 大会发言 |
异基因造血干细胞移植治疗婴儿白血病的临床研究 |
|
||||
| 2 | 16:35-16:40 | 大会发言 |
Efficacy and safety of CART2 therapy in children with B-ALL relapse after co-administration of CD19/CD22 CAR-T cells |
|
||||
| 3 | 16:40-16:45 | 大会发言 |
异基因造血干细胞移植治疗儿童EB病毒阳性T/NK细胞淋巴组织增殖性疾病疗效分析 |
|
||||
| 4 | 16:45-16:50 | 大会发言 |
Homoharringtonine Added to CLAG regimen Improves Outcome of pediatric Relapsed/Refractory AML: A Multicenter prospective Study |
|
||||
| 5 | 16:50-16:55 | 大会发言 |
PI3Kδ抑制剂增强曲美替尼对PTPN11突变型幼年粒单核细胞白血病的抗肿瘤效应 |
|
||||
| 6 | 16:55-17:00 | 大会发言 |
CAR-T治疗难治/复发儿童ALL单细胞水平免疫微环境演进研究 |
|
||||
| 7 | 17:00-17:05 | 大会发言 |
异基因造血干细胞移植治疗46例2岁以下噬血细胞综合征的疗效及预后分析 |
|
||||
| 8 | 17:05-17:10 | 大会发言 |
Emapalumab in Pediatric Patients with High-grade Cytokine Release Syndrome Associated with CAR T-cell Therapy |
|
||||
| 9 | 17:10-17:15 | 大会发言 |
儿童AML诱导失败的多队列预测模型构建与验证 |
|
||||
| 10 | 17:15-17:20 | 大会发言 |
体外祛除ab+T细胞半相合造血干细胞移植治疗重症联合免疫缺陷病 |
|
||||